US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
112 deals · US$144bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Marea Therapeutics | – | Lisata Therapeutics | Acquisition | Announced | – | Biotech+1 | Goodwin (sell-side) |
| Sep 2026 | Aethlon Medical | – | – | Merger | Announced | – | Biotech | Gibson DunnMaxim GroupProcopio, Cory, Hargreaves & SavitchWedbush Securities |
| Sep 2026 | Santersus AG | – | Xenetic Biosciences | Acquisition | Announced | – | Medtech+1 | Mintz (sell-side)Lex Futura (sell-side)Holland & Knight (buy-side)Canaccord Genuity (buy-side) |
| Sep 2026 | RIGImmune | – | Leyden Labs | Acquisition | Completed | – | Biotech+1 | Gunderson Dettmer (sell-side) |
| Sep 2026 | Polaris | Demea Agro | Motion Equity Partners | Acquisition | Announced | – | Food Ingredients+2 | Goodwin (sell-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Aug 2026 | Merida Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 2,875.0 | Biotech+1 | Goodwin (sell-side)Centerview Partners (sell-side)Ropes & Gray (buy-side) |
| Aug 2026 | Ambros Therapeutics | – | Werewolf Therapeutics | Merger | Announced | 500.0 | Biotech+2 | Sidley Austin (buy-side)Cooley (sell-side)Piper Sandler (buy-side) |
| Aug 2026 | Alesta Therapeutics | – | BioMarin Pharmaceutical | Acquisition | Announced | 275.0 | Biotech+2 | J.P. Morgan (sell-side)Goodwin (sell-side)NautaDutilh (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Aug 2026 | Slate Medicines | – | Fulcrum Therapeutics | Merger | Announced | – | Biotech+1 | Goodwin (buy-side)Cooley (sell-side)Wedbush Securities (sell-side)Leerink Partners (buy-side) |
| Aug 2026 | Redx Pharma | – | Skye Bioscience | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Cooley (sell-side)Stifel (buy-side)Morrison & Foerster (buy-side) |
| Aug 2026 | Actio Biosciences | – | Jazz Pharmaceuticals | Acquisition | Announced | 820.0 | Biotech+2 | J.P. Morgan (sell-side)Centerview Partners (sell-side)Cooley (sell-side)Moelis & Company (buy-side)Hogan Lovells Cadwalader (buy-side) |
| Aug 2026 | assets, business operations and customer relationships | – | NueCell Bio | Asset sale | Announced | – | Pharma Services+1 | Goodwin (buy-side) |
| Aug 2026 | Cy Biopharma | – | Ensysce Biosciences | Acquisition | Completed | – | Biotech+1 | H.C. Wainwright & Co.Orrick (sell-side)Wedbush Securities (sell-side)Troutman Pepper Locke (buy-side)Tungsten Advisors (buy-side) |
| Aug 2026 | Alkeus Pharmaceuticals | – | Tarsus Pharmaceuticals | Acquisition | Announced | 450.0 | Biotech+2 | Jefferies (sell-side)Latham & Watkins (sell-side)Barclays (buy-side)Gunderson Dettmer (buy-side) |
| Aug 2026 | MIMETAS | – | BRUKER | Acquisition | Completed | – | Life Sciences+1 | Raymond James |
| Jul 2026 | Neurimmune's royalty interest in AstraZeneca's cliramitug | Neurimmune | Royalty Pharma | Asset sale | Announced | 250.0 | Pharma+1 | Goodwin (buy-side) |
| Jul 2026 | Synlogic | – | – | Merger | Announced | – | Biotech+1 | Lucid Capital Markets (sell-side)Mintz (sell-side)Fenwick & West (buy-side) |
| Jul 2026 | Vidya Therapeutics | – | Processa Pharmaceuticals | Acquisition | Completed | – | Biotech+1 | Leerink Partners (sell-side)Cooley (sell-side)Tungsten Advisors (buy-side)Katten Muchin Rosenman (buy-side) |
| Jul 2026 | Forte Biosciences | – | argenx SE | Acquisition | Announced | 2,200.0 | Biotech+1 | Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goldman Sachs (buy-side)Freshfields (buy-side)Innisfree M&A (buy-side) |
| Jul 2026 | OHB Pediatrics Ltd. d/b/a Oak Hill Bio | – | Research Alliance Corporation III | Merger | Announced | – | Biotech+2 | Goodwin (sell-side)Leerink Partners (buy-side)Cooley (buy-side) |
| Jul 2026 | Neuphoria Therapeutics | – | Scancell Holdings | Acquisition | Announced | – | Biotech+1 | H.C. Wainwright & Co. (sell-side)WG Partners (sell-side)Winston Taylor (sell-side)Leerink Partners (buy-side)Cooley (buy-side) |
| Jul 2026 | BioLife Solutions | – | Repligen | Acquisition | Announced | 1,500.0 | Life Sciences+1 | Centerview Partners (sell-side)K&L Gates (sell-side)Goodwin (buy-side)Perella Weinberg Partners (buy-side)Goldman Sachs (buy-side) |
| Jul 2026 | Avere Therapeutics | – | Hansoh Pharmaceutical Group Co. | Stake | Announced | – | Biotech+2 | Goodwin (buy-side) |
| Jul 2026 | AtaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 2,800.0 | Biotech+2 | Moelis & Company (sell-side)Centerview Partners (sell-side)Latham & Watkins (sell-side)Citi (sell-side)Cooley (sell-side)Sullivan & Cromwell (sell-side)Goldman Sachs (buy-side)Ropes & Gray (buy-side) |
| Jul 2026 | Kira Pharmaceuticals | – | Jasper Therapeutics | Acquisition | Completed | – | Biotech+1 | Piper Sandler (sell-side)DLA Piper (sell-side)H.C. Wainwright & Co. (buy-side)Paul Hastings (buy-side) |
| Jul 2026 | Senti Holdings, Inc. (Midco) | Senti Biosciences Holdings | Celadon Partners SPV 35 | Acquisition | Announced | – | Biotech+2 | Lincoln International (sell-side)Gunderson Dettmer (sell-side)McDermott Will & Schulte (buy-side) |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Announced | – | Biotech+1 | Sullivan & CromwellSidley Austin (buy-side)Gibson Dunn (sell-side)Wedbush Securities (sell-side)Tungsten Advisors (buy-side) |
| Jul 2026 | iRenix Medical | – | Tarsus Pharmaceuticals | Acquisition | Announced | 75.0 | Ophthalmology+2 | Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side) |
| Jul 2026 | Crinetics Pharmaceuticals | – | Vertex Pharmaceuticals | Acquisition | Announced | 10,000.0 | Biotech+2 | Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Jul 2026 | BridgeBio | – | Sixth Street | Stake | Completed | 1,000.0 | Biotech+1 | Sullivan & Cromwell (buy-side)Evercore (buy-side) |
| Jul 2026 | Kestrel | – | AbbVie | Acquisition | Announced | – | Biotech | Lazard |
| Jul 2026 | MeiraGTx Holdings | – | Oberland Capital Management | Stake | Announced | – | Biotech+1 | Latham & Watkins (sell-side) |
| Jun 2026 | Kartos Therapeutics | – | Ipsen | Acquisition | Announced | 450.0 | Biotech+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)DLA Piper (sell-side)Orrick (buy-side) |
| Jun 2026 | Talawar Therapeutics | – | JATT II Acquisition Corp | Merger | Announced | – | Biotech+1 | Cooley (sell-side)Greenberg Traurig (buy-side) |
| Jun 2026 | Theravance Biopharma | – | Zymeworks | Acquisition | Pending | 929.0 | Pharma+1 | Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side) |
| Jun 2026 | Remix Therapeutics | – | Passage Bio | Merger | Pending | – | Biotech+2 | Wedbush SecuritiesRBC Capital MarketsCanaccord GenuityLatham & Watkins (sell-side)Fenwick & West (buy-side) |
| Jun 2026 | Serapha Bio | – | Boundless Bio | Merger | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side)Lucid Capital Markets (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Apogee Therapeutics | – | AbbVie | Acquisition | Pending | 10,900.0 | Biotech+2 | Goldman Sachs (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Paul, Weiss (buy-side)Morgan Stanley (buy-side) |
| Jun 2026 | 4E Therapeutics | – | Eli Lilly and Company | Acquisition | Completed | – | Biotech+1 | Wilson Sonsini Goodrich & Rosati (sell-side) |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Completed | – | Biotech+2 | Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side) |
| Jun 2026 | Nuvalent | – | GSK | Acquisition | Pending | 10,600.0 | Biotech+2 | Sullivan & CromwellCenterview Partners (sell-side)Ropes & Gray (sell-side)Jefferies (sell-side)Sidley Austin (sell-side)Leerink Partners (buy-side)Citi (buy-side)Davis Polk (buy-side)Slaughter and May (buy-side)Innisfree M&A (buy-side) |
| Jun 2026 | Vega Therapeutics | Star Therapeutics | Incyte | Acquisition | Completed | 1,250.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Morgan Stanley (sell-side)Fenwick & West (sell-side)Goodwin (buy-side) |
| Jun 2026 | Standard BioTools | – | – | Merger | Pending | 460.0 | Biotech+2 | Wedbush Securities (sell-side)Fenwick & West (sell-side)Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side) |
| Jun 2026 | Genesis Molecular AI | – | Incyte | Stake | Announced | 40.0 | AI+1 | Goodwin (buy-side) |
| Jun 2026 | Avenzo Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+2 | Leerink Partners (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Jun 2026 | Sevasemten and Edgewise muscular dystrophy business | Edgewise Therapeutics | Servier | Asset sale | Completed | 1,550.0 | Biotech+2 | LazardCenterview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side) |
| May 2026 | Curevo Vaccine | – | Eli Lilly | Acquisition | Pending | 1,500.0 | Biotech+1 | Cooley (sell-side)Centerview Partners (sell-side) |
| May 2026 | Vaccine Company | – | Lilly | Acquisition | Announced | 1,550.0 | Biotech+1 | Lazard (sell-side)Cooley (sell-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built